Combination therapy for bile duct cancer that has not spread
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that cannot be removed by surgery or has come back after treatment.
- The cancer has not spread outside the liver.
- You have not had prior systemic therapy (like chemotherapy or targeted drugs) or transarterial interventional therapy (like TACE) for this cancer.
- You are in generally good health (able to care for yourself, ECOG score 0 or 1) and have adequate liver function (Child-Pugh class A).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.